Use and cost of a hypoglossal nerve stimulator device for obstructive sleep apnea between 2015 and 2018
JAMA Otolaryngology—Head & Neck Surgery Aug 26, 2019
Rathi VK, et al. - Given that more than 17 million patients in the US have obstructive sleep apnea, a condition related to sequelae like daytime somnolence, motor vehicle crashes, and cardiovascular disease, researchers conducted this investigation to analyze the use and cost of a hypoglossal nerve stimulator device for obstructive sleep apnea between 2015 and 2018. Continuous positive airway pressure systems are the first-line therapy for obstructive sleep apnea, although patient non-compliance often limits the efficacy of such therapy. Findings revealed that there are second-line treatments (eg, oral appliances and palatal surgery), but there is limited support for such alternatives in the available evidence.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries